Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Obesity01:24

Obesity

1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Binge Eating Disorders01:23

Binge Eating Disorders

426
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
426
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Bulimia Nervosa01:30

Bulimia Nervosa

692
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
692

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis.

Obesity science & practice·2026
Same author

GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

TOS/OMA/OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action.

Obesity (Silver Spring, Md.)·2026
Same author

Clinical and Preclinical Obesity in Korean Adults from 2014 to 2023.

Diabetes & metabolism journal·2026
Same author

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.

JAMA cardiology·2025
Same author

Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.

The New England journal of medicine·2025
Same journal

The Clinical Impact of Patient Embarrassment in Gynecology: A Comprehensive Review of Barriers, Consequences, and Mitigation Strategies.

Medical sciences (Basel, Switzerland)·2026
Same journal

Physical Performance as a Predictor of Length of Hospital Stay in Patients Undergoing Open-Heart Surgery: A Multicenter Prospective Study.

Medical sciences (Basel, Switzerland)·2026
Same journal

Renal Involvement in Pediatric Small-Vessel Vasculitis: A Comprehensive Review of Clinical Impact, Diagnosis, and Management.

Medical sciences (Basel, Switzerland)·2026
Same journal

MRI-Based Radiomics and Artificial Intelligence for Prediction of Recurrence and Prognostic Outcomes in Oral Tongue Squamous Cell Carcinoma: A Systematic Review with Functional Meta-Synthesis.

Medical sciences (Basel, Switzerland)·2026
Same journal

Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets.

Medical sciences (Basel, Switzerland)·2026
Same journal

Narrative Review of Digital Twins in the Health Domain: Development, Application, and Evidence Consolidation.

Medical sciences (Basel, Switzerland)·2026
查看所有相关文章

相关实验视频

Updated: Jan 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

909

除了肥胖之外的其他问题

George A Bray1, Donna H Ryan1

  • 1Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.

Medical sciences (Basel, Switzerland)
|September 22, 2025
PubMed
概括
此摘要是机器生成的。

建议对肥胖进行新的诊断类别,包括"临床前肥胖". 这旨在通过考虑脂肪的分布和功能来改善诊断,而不仅仅是身体质量指数 (BMI),可能会使用诸如"肥胖"等术语.

关键词:
身体质量指数 (BMI) 是指身体质量指数.中部脂肪的中心脂肪.临床肥胖症 临床肥胖症肥胖的耻辱是肥胖的耻辱.

更多相关视频

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.3K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.3K

相关实验视频

Last Updated: Jan 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

909
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.3K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.3K

科学领域:

  • 医学诊断 医学诊断 医学诊断
  • 公共卫生 公共卫生
  • 代谢障碍 代谢障碍 代谢障碍

背景情况:

  • 肥胖诊断已经从生命保险表演变为身体质量指数 (BMI).
  • 体重指数有局限性,肥胖流行需要改进的诊断工具.
  • 脂肪的分布和功能是肥胖的关键方面,由Jean Vague率先提出.

研究的目的:

  • 讨论关于增加体脂和异常分布的改进诊断方法.
  • 探索肥胖的替代术语,例如脂肪或健康体重.
  • 解决当前肥胖诊断标准的局限性和需要新的指导方针.

主要方法:

  • 对肥胖的历史诊断标准的审查.
  • 讨论身体质量指数 (BMI) 的限制.
  • 探索脂肪分布和功能在肥胖中的作用.

主要成果:

  • 关于一个新的诊断类别"临床前肥胖"的建议.
  • 突出需要诊断指南超越BMI.
  • 确定"肥胖"和"健康体重"作为潜在的替代术语.

结论:

  • 目前用于肥胖的诊断方法,主要是BMI,是不够的.
  • 需要新的诊断指南来解释脂肪的分布和功能.
  • 像"肥胖"这样的替代术语可能会减少与肥胖相关的耻辱.